Last updated: February 20, 2026
What is NDC 45802-0438?
NDC 45802-0438 corresponds to Liposomal Amphotericin B (brand name: AmBisome). It is an antifungal used primarily to treat invasive fungal infections, including cryptococcal meningitis, aspergillosis, and visceral leishmaniasis in high-risk populations. It is administered intravenously and supplied in a liposomal formulation designed to reduce toxicity compared to conventional Amphotericin B.
Market Overview
Market Size and Demand Drivers
- The global antifungal market was valued at approximately USD 10.2 billion in 2022.
- Liposomal Amphotericin B accounted for an estimated 18% of the antifungal market share, roughly USD 1.8 billion.
- Growth drivers include increasing incidence of invasive fungal infections, expanding indications, and broader use in immunocompromised populations, especially post-COVID-19 and in transplant recipients.
Key Market Participants
- Bristol-Myers Squibb (brand: AmBisome) holds significant market share.
- Other competitors include generic manufacturers offering amphotericin B lipid formulations.
- Significant price competition exists among generics due to patent expirations in recent years.
Patents and Regulatory Status
- AmBisome's primary patents expired around 2018 in the U.S.
- Market share shifts toward biosimilars and generic producers, impacting pricing.
Price Trends and Projections
Current Pricing Landscape (as of 2023)
| Formulation Type |
Price per 50 mg vial |
Notes |
| Branded (AmBisome) |
USD 400 - USD 600 |
Premium, brand reputation, patent rights in select markets |
| Generics (Liposomal formulations) |
USD 150 - USD 300 |
Price varies by manufacturer and region; margins compressed post-patent expiry |
Historical Price Dynamics (2017-2022)
- Prices for AmBisome remained stable from 2017 up to 2018, averaging USD 500 per 50 mg vial.
- Post-2018 patent expiration, generic competition led to a steep decline in prices, down approximately 20-30% in North American and European markets.
- In emerging markets, prices are lower, averaging USD 150-250 per 50 mg vial, driven by regional healthcare policies and economics.
Future Price Projections (2023-2028)
| Year |
Expected Price per 50 mg vial |
Key Factors |
| 2023 |
USD 150 - USD 250 |
Market stabilization, increased generic penetration |
| 2024 |
USD 140 - USD 240 |
Entry of new biosimilars, further discounts |
| 2025 |
USD 130 - USD 220 |
Manufacturing efficiencies, regional price pressures |
| 2026 |
USD 120 - USD 210 |
Market saturation, price competition intensifies |
| 2027 |
USD 110 - USD 200 |
Potential impact of biosimilar patents, governmental price controls |
| 2028 |
USD 100 - USD 190 |
Price stabilization at lower bounds, regional disparities persist |
Key Geographic Variations
- North America: Prices tend to be higher due to higher healthcare costs, with stable or declining prices as generics dominate.
- Europe: Similar trends to North America, with some countries implementing price controls.
- Emerging Markets: Prices remain significantly lower, unaffected by patent expirations.
Market Outlook and Key Drivers
- Increasing use in neglected fungal diseases like leishmaniasis expands total market volume but exerts downward pressure on unit pricing.
- Approval of biosimilars is expected to reduce the average selling price further, potentially by 10-20% annually over the next five years.
- Expanded indications or combination therapies could temporarily stabilize or increase prices.
- Regional regulatory policies will influence pricing trajectories, especially in Europe and Asia.
Risks and Opportunities
Risks
- Entry of biosimilars and generics significantly pressures pricing.
- Policy changes, including price caps or reimbursement restrictions, could diminish profitability.
- Competitive pressures from new antifungal agents, such as novel azoles or combination therapies.
Opportunities
- Developing new delivery mechanisms or formulations could command premium pricing.
- Expanding into emerging markets remains a growth avenue, though price flexibility is limited.
- Strategic partnerships for biosimilar development could reduce manufacturing costs.
Key Takeaways
- Generic competition has depressed prices of liposomal Amphotericin B, with current average prices ranging from USD 150-300 per 50 mg vial.
- Market growth driven by increasing fungal infection incidence is offset by declining per-unit prices.
- Price projections indicate a continued decline to approximately USD 100-200 per vial within five years, considering biosimilar market penetration.
- Regional policy environments and new antifungal developments may influence pricing variance regionally.
- Opportunities exist in biosimilar production, novel formulations, and emerging market expansion.
FAQs
1. How does biosimilar entry influence liposomal Amphotericin B pricing?
Biosimilar entry typically reduces prices by introducing more competition, with potential declines of 10-20% annually as market share shifts from the brand to generics.
2. What factors could cause prices to stabilize or rise?
Price stabilization or increases could result from new indications, formulation improvements, or regulatory constraints limiting generic entry.
3. How do regional policies impact pricing?
Price controls, reimbursement policies, and procurement practices vary by country and can lead to significant regional price disparities.
4. Is there potential for market growth despite declining prices?
Yes, driven by rising global fungal infections and expanding indications, especially in low- and middle-income regions.
5. What is the outlook for branded vs. generic pricing?
Branded prices are decreasing but remain higher than generics; over time, branded formulations may command premium prices only in niche markets or specialized indications.
References
[1] Market Research Future. (2022). Global antifungal market research report.
[2] EvaluatePharma. (2022). Top 10 antifungals by sales.
[3] IMS Health. (2022). Pharmaceutical pricing and market trends report.
[4] U.S. Food and Drug Administration. (2021). Patent and exclusivity status for AmBisome.
[5] European Medicines Agency. (2022). Biosimilar guidelines and approval process.
